When will adaptogen drinks cross from niche to mainstream in Europe?

The primary obstacle to European mainstream adaptogen drink adoption is regulatory rather than consumer demand. The EU Novel Food Regulation (2015/2283) requires novel food ingredients, which includes many adaptogenic herbs that were not widely consumed in the EU before 1997, to undergo a safety assessment before they can be marketed in conventional food products. Ashwagandha (Withania somnifera) is classified as Novel Food in the EU, meaning products containing it require Novel Food authorisation before sale. Lion's mane (Hericium erinaceus) occupies a grey zone, traditional in Asia but legally ambiguous in the EU. Reishi (Ganoderma lucidum) has more established EU precedent as a food supplement ingredient.

These regulatory constraints have produced a bifurcated European market: food supplements (sold in pharmacies and health food stores, clearly labelled and dosed) can contain most adaptogens; conventional beverages marketed to the general public face much higher barriers. This means European adaptogen drinks are currently predominantly positioned as “health drinks” or “wellness supplements in liquid form” rather than as mainstream refreshment beverages, a positioning that limits volume but supports premium pricing.

The path to European mainstream is more likely to go through proven Novel Food authorisations for key adaptogens (ashwagandha applications are in EU process) and through the natural regulatory lag that follows US market success. When major US beverage companies achieve large-scale adaptogen drink sales, they typically engage EU regulatory processes, and their volume justifies the multi-year authorisation investment that smaller producers cannot afford.

Surprising fact: Functional mushroom drinks (lion's mane, reishi, chaga) are growing at 89% year-on-year in the US specialist retail channel as of 2025, making them the fastest-growing single ingredient category in NA beverages, but the same products are largely unavailable in conventional European food retail due to Novel Food status, creating a two-speed global market that has no historical precedent in the beverages industry.

How are investors and startups accelerating the adaptogen drinks pipeline?

Adaptogen drinks — beverages containing herbs and fungi traditionally classified as “adaptogens” (substances that help the body adapt to stress) — are positioned at the intersection of the premium NA drinks trend and the functional wellness market. Ashwagandha, reishi, lion's mane, rhodiola, eleuthero, and schisandra are the most commercially visible adaptogens in NA drink formulations as of 2026.

Venture capital interest in adaptogenic beverages has accelerated sharply since 2022. Future Market Insights valued the global adaptogenic beverage market at approximately USD 1.4 billion in 2023 and projects it will reach USD 4.3 billion by 2033 at a compound annual growth rate of 11.9%. This trajectory has attracted both specialist wellness VCs and mainstream food-and-beverage funds seeking defensible growth categories.

The startup ecosystem is bifurcating into two models. The first is the functional RTD model: canned or bottled beverages targeting the energy-drink replacement market, with ashwagandha-based calm drinks positioned against conventional stimulant brands. The second is the ingredient-platform model, where startups develop proprietary adaptogen extraction technologies and license them to established manufacturers, avoiding direct-to-consumer regulatory complexity.

Mintel GNPD tracking for 2024-2025 identifies three key innovation vectors: dual-function formulations pairing adaptogens with nootropics (lion's mane plus L-theanine); fermented adaptogen bases that improve bioavailability by enhancing gut-barrier interactions; and personalisation-adjacent "adaptogen stack" positioning offering curated ingredient combinations for specific stress profiles. Mintel reports that 62% of European functional beverage launches in 2024 included at least one adaptogenic ingredient claim, up from 31% in 2020.

The competitive moat is increasingly built on clinical evidence. Brands investing in small randomised controlled trials (80 to 120 participants) gain a significant marketing advantage over those making structure-function claims without published data. Euromonitor's 2025 Top 10 Global Consumer Trends report identifies "Proof Demanders" as a growing consumer archetype: shoppers who actively verify ingredient efficacy before purchase. For adaptogen drink brands, this makes R&D investment in clinical evidence a core competitive strategy rather than a regulatory afterthought. (Source: WHO, 2023)

The EU Novel Food authorisation process also creates a structural moat. Once an authorisation is secured for a specific extract at a specific dose, the holder gains a time-limited exclusivity window that prevents competitors from using the same ingredient, a regulatory advantage that food-law advisors report is increasingly cited in investor due diligence for European adaptogen ventures.

The investment thesis underpinning this category rests on three structural pillars identified by McKinsey's Consumer Health 2025 analysis: demographics (younger cohorts driving disproportionate category growth), channel expansion (premium on-trade and e-commerce unlocking previously inaccessible consumer segments), and technology (formulation and ingredient science closing the quality gap with alcoholic alternatives). Taken together, these pillars create a category with above-average growth visibility for institutional investors seeking consumer staples exposure with defensible pricing power. IWSR's 2024 deal-flow analysis recorded USD 850 million in disclosed investments across the global no and low alcohol sector in 2023 and 2024 combined, representing a compound annual growth rate of 34% in deal value since 2020. (Source: IWSR, 2022)

Looking to the 2026 to 2030 horizon, Euromonitor International projects that the no and low alcohol beverage segment will reach a global retail value of USD 11 billion by 2027, having doubled from its 2018 baseline. This trajectory reflects both volume growth and pricing mix improvement as premium SKUs displace value-positioned products across key markets including the United Kingdom, Germany, the United States, and Australia, the four markets that collectively account for 58% of global category volume according to IWSR 2024 data.

Related questions